Novizan (南京诺唯赞生物科技有限公司), founded in 2012 and based in Nanjing, operates a technology platform that develops, produces and sells key raw materials and terminal reagents for life sciences, in vitro diagnostics (IVD) and biopharma. Its product set includes enzymes, antigens, antibodies and a range of diagnostic reagents across multiple product lines. The company emphasizes import substitution and claims domestic competitiveness across full product lines versus imported alternatives. During the COVID-19 pandemic Novizan developed SARS‑CoV‑2 nucleic acid test core materials and a SARS‑CoV‑2 IgM/IgG colloidal‑gold antibody test kit that received China Class III medical device registration and multiple overseas certifications. Management highlights strong R&D and commercialization capabilities and says the firm provides customized products and services to molecular diagnostics companies and research institutions. The company plans to continue industrializing core raw materials and reagents and to expand downstream into application areas that are currently import‑dominated.

Total raised

$78M

Funding rounds

1

Latest round

Series C

Latest activity

May 2020